Antiphospholipid syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Primary Prevention==
==Primary Prevention==
The primary prevention of antiphospholipid syndrome is as follows:<ref name="pmid24449256">{{cite journal| author=Nalli C, Andreoli L, Casu C, Tincani A| title=Management of recurrent thrombosis in antiphospholipid syndrome. | journal=Curr Rheumatol Rep | year= 2014 | volume= 16 | issue= 3 | pages= 405 | pmid=24449256 | doi=10.1007/s11926-013-0405-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24449256  }} </ref><ref name="pmid15507275">{{cite journal| author=Erkan D, Lockshin MD| title=How much warfarin is enough in APS related thrombosis? | journal=Thromb Res | year= 2004 | volume= 114 | issue= 5-6 | pages= 435-42 | pmid=15507275 | doi=10.1016/j.thromres.2004.06.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15507275  }} </ref><ref name="pmid7885428">{{cite journal| author=Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR| title=The management of thrombosis in the antiphospholipid-antibody syndrome. | journal=N Engl J Med | year= 1995 | volume= 332 | issue= 15 | pages= 993-7 | pmid=7885428 | doi=10.1056/NEJM199504133321504 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7885428  }} </ref>
The primary prevention of antiphospholipid syndrome is as follows:<ref name="pmid24449256">{{cite journal| author=Nalli C, Andreoli L, Casu C, Tincani A| title=Management of recurrent thrombosis in antiphospholipid syndrome. | journal=Curr Rheumatol Rep | year= 2014 | volume= 16 | issue= 3 | pages= 405 | pmid=24449256 | doi=10.1007/s11926-013-0405-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24449256  }} </ref><ref name="pmid15507275">{{cite journal| author=Erkan D, Lockshin MD| title=How much warfarin is enough in APS related thrombosis? | journal=Thromb Res | year= 2004 | volume= 114 | issue= 5-6 | pages= 435-42 | pmid=15507275 | doi=10.1016/j.thromres.2004.06.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15507275  }} </ref><ref name="pmid7885428">{{cite journal| author=Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR| title=The management of thrombosis in the antiphospholipid-antibody syndrome. | journal=N Engl J Med | year= 1995 | volume= 332 | issue= 15 | pages= 993-7 | pmid=7885428 | doi=10.1056/NEJM199504133321504 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7885428  }} </ref>
* Anticoagulation with low-dose aspirin or warfarin in patients with risk factors for arterial and venous thrombosis.
* Anticoagulation with low-dose [[aspirin]] or [[warfarin]] in patients with risk factors for [[Artery|arterial]] and venous [[thrombosis]].
* Minimizing the contribution of reversible risk factors for recurrent thrombosis.
* Minimizing the contribution of reversible risk factors for recurrent thrombosis.
* A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.
* A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.

Revision as of 19:53, 14 April 2018

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome primary prevention

CDC on Antiphospholipid syndrome primary prevention

Antiphospholipid syndrome primary prevention in the news

Blogs on Antiphospholipid syndrome primary prevention

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

The primary prevention of antiphospholipid syndrome is anticoagulation with low-dose aspirin or warfarin in patients with risk factors for arterial and venous thrombosis, daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies, minimizing the contribution of reversible risk factors for recurrent thrombosis and use of statins in patients with hyperlipidemia.

Primary Prevention

The primary prevention of antiphospholipid syndrome is as follows:[1][2][3]

  • Anticoagulation with low-dose aspirin or warfarin in patients with risk factors for arterial and venous thrombosis.
  • Minimizing the contribution of reversible risk factors for recurrent thrombosis.
  • A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.
  • Use of statins in patients with hyperlipidemia.
Primary thromboprophylaxis
Patients with systemic lupus erythematosus and lupus anticoagulant and/or persistently positive anticardiolipin Hydroxychloroquine and consider low-dose aspirin
Patients with obstetric antiphospholipid syndrome Low-dose aspirin or no therapy
Asymptomatic carriers of antiphospholipid antibodies No therapy or low dose aspirin
All patients with antiphospholipid antibodies Strict control of vascular risk factors
High-risk situations (surgery, post partum, long-lasting immobilisation) Adequate thromboprophylaxis

References

  1. Nalli C, Andreoli L, Casu C, Tincani A (2014). "Management of recurrent thrombosis in antiphospholipid syndrome". Curr Rheumatol Rep. 16 (3): 405. doi:10.1007/s11926-013-0405-4. PMID 24449256.
  2. Erkan D, Lockshin MD (2004). "How much warfarin is enough in APS related thrombosis?". Thromb Res. 114 (5–6): 435–42. doi:10.1016/j.thromres.2004.06.010. PMID 15507275.
  3. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995). "The management of thrombosis in the antiphospholipid-antibody syndrome". N Engl J Med. 332 (15): 993–7. doi:10.1056/NEJM199504133321504. PMID 7885428.

Template:WH Template:WS